By 2026, biopharma licensing deals involving Chinese originators have surpassed $130 billion in cumulative value. Pfizer and GSK have led the charge, with Chinese assets now comprising 40% of all…
The 2025–2026 metabolic landscape is defined by a massive shift in patient access: the transition from weekly injections to daily oral small molecules. As of March 2026, the oral GLP-1…
By early 2026, Chinese biotech innovation has moved from a “fast-follower” role to a primary global engine for first-in-class oncology assets. Chinese firms now drive 70% of the global ADC…
As the therapeutic architecture of targeted oncology grows exponentially more complex, the state of ADC Manufacturing reveals a massive industry pivot. Producing an antibody-drug conjugate is notoriously difficult; it requires…
The oncology sector is experiencing a massive leap forward as Bispecific ADCs hit the clinic. While first-generation antibody-drug conjugates proved the viability of targeted chemotherapy, they frequently encountered roadblocks like…
The first generation of obesity drugs faced a critical clinical challenge: nearly 25-40% of the weight lost was comprised of lean muscle and bone mass. In 2026, the focus has…
The artificial intelligence landscape in biopharma during 2025 and 2026 is defined by a rapid transition from exploratory pilot programs to massive, industrialized integrations across the drug development lifecycle. The…
The 2025–2026 metabolic landscape is defined by a massive shift in patient access: the transition from weekly injections to daily oral small molecules. As of March 2026, the oral GLP-1…
The biotechnology sector is experiencing a massive influx of investment and clinical progression. A deep dive into the RNA Therapeutics Market 2026 reveals a robust global pipeline featuring approximately 1,297…
As artificial intelligence industrializes the drug development lifecycle, the most significant productivity gains in 2026 are occurring in the regulatory phase. The preparation of a submission is a massive undertaking,…